Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Ciofini

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Current Oncology (Toronto, Ont.)|July 28, 2023
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic ImplicationsEmanuele Cencini, Anna Sicuranza, Sara Ciofini, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 21, 2020
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopeniaVincenzo Sammartano, Adele Santoni, Marzia Defina, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 10, 2025
Efficacy and Safety of Teclistamab Followed by Autologous Stem Cell Transplant in Functional High-risk and Triple-class Refractory Multiple MyelomaVincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, et al.
Human Vaccines & Immunotherapeutics|April 11, 2022
Anti CD38 monoclonal antibodies for multiple myeloma treatmentAlessandro Gozzetti, Sara Ciofini, Martina Simoncelli, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Drug resistance and minimal residual disease in multiple myelomaAlessandro Gozzetti, Sara Ciofini, Anna Sicuranza, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Anti-BCMA novel therapies for multiple myelomaVincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Frontiers in Oncology|September 25, 2024
Management of infections for patient treated with ibrutinib in clinical practiceClaudia Baratè, Ilaria Scortechini, Sara Ciofini, et al.
Clinical Case Reports|October 22, 2020
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemiaElisabetta Zappone, Emanuele Cencini, Marzia Defina, et al.
Journal of Personalized Medicine|December 29, 2022
Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRIAdele Santoni, Martina Simoncelli, Marta Franceschini, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal AntibodiesFederico Caroni, Vincenzo Sammartano, Paola Pacelli, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Current Oncology (Toronto, Ont.)|July 28, 2023
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic ImplicationsEmanuele Cencini, Anna Sicuranza, Sara Ciofini, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 21, 2020
Efficacy and safety of eltrombopag during conception and first trimester of pregnancy in a case of refractory severe immune thrombocytopeniaVincenzo Sammartano, Adele Santoni, Marzia Defina, et al.
Mediterranean Journal of Hematology and Infectious Diseases|July 10, 2025
Efficacy and Safety of Teclistamab Followed by Autologous Stem Cell Transplant in Functional High-risk and Triple-class Refractory Multiple MyelomaVincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, et al.
Human Vaccines & Immunotherapeutics|April 11, 2022
Anti CD38 monoclonal antibodies for multiple myeloma treatmentAlessandro Gozzetti, Sara Ciofini, Martina Simoncelli, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Drug resistance and minimal residual disease in multiple myelomaAlessandro Gozzetti, Sara Ciofini, Anna Sicuranza, et al.
Cancer Drug Resistance (Alhambra, Calif.)|April 17, 2023
Anti-BCMA novel therapies for multiple myelomaVincenzo Sammartano, Marta Franceschini, Sara Fredducci, et al.
Frontiers in Oncology|September 25, 2024
Management of infections for patient treated with ibrutinib in clinical practiceClaudia Baratè, Ilaria Scortechini, Sara Ciofini, et al.
Clinical Case Reports|October 22, 2020
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemiaElisabetta Zappone, Emanuele Cencini, Marzia Defina, et al.
Journal of Personalized Medicine|December 29, 2022
Functional Imaging in the Evaluation of Treatment Response in Multiple Myeloma: The Role of PET-CT and MRIAdele Santoni, Martina Simoncelli, Marta Franceschini, et al.
Pharmaceuticals (Basel, Switzerland)|February 26, 2025
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal AntibodiesFederico Caroni, Vincenzo Sammartano, Paola Pacelli, et al.
Pageof 3